The state’s own drug-checking program finds a median of four active substances in a single sample. That is not people mixing on purpose. That is what the supply has become.
- Polysubstance is now the default, not the exception. Massachusetts drug-checking found a median of four active substances per sample.
- Most of it is not intentional. People buying one thing are receiving several.
- Fentanyl was present in 89 percent of screened overdose decedents in the state’s 2024 reporting.
- Xylazine does not respond to naloxone, and it is not an opioid, which changes both overdose response and withdrawal management.
- Withdrawal from a mixed supply needs more than one protocol running at the same time, which is the clinical reason unsupervised detox has gotten more dangerous.
Ask somebody in the Merrimack Valley what they use and you will usually get one answer. Ask a toxicology screen and you get four.
That gap is the most consequential thing that has changed about addiction treatment in Massachusetts over the past decade, and it has changed what a safe detox has to account for. Serenity at Summit runs medically monitored detox in Haverhill, just off Interstate 495, and the clinical picture arriving at the door now looks meaningfully different from the one that arrived ten years ago.
What the Massachusetts Data Actually Shows
The Massachusetts Department of Public Health operates a drug-checking program that analyzes samples of the supply people are actually buying. In the state’s 2024 opioid-involved overdose reporting, those samples carried a median of four active substances plus two inactive ones.
Four. In the median sample, not the outlier.
The overdose data tells the same story from the other direction. Among 1,187 screened decedents in that 2024 reporting, 89 percent were fentanyl-positive. Fentanyl overtook heroin in Massachusetts back in 2015 and has not given the position back. What people describe as heroin has for years been mostly or entirely fentanyl, often alongside other things nobody selected.
Numbers like these rot, so the year matters: these are from the state’s 2024 reporting, published in 2026. The direction has been consistent for long enough that the direction is the durable finding.
The Combinations That Actually Show Up
Some of this is deliberate and some is entirely not, and the distinction matters clinically less than people expect.
Fentanyl with stimulants is the pattern that has grown fastest. Cocaine and methamphetamine increasingly test positive for fentanyl, sometimes through contamination and sometimes because it was added. A person who has never used opioids and has no tolerance can encounter fentanyl through a stimulant, which is why naloxone matters to people who would not describe themselves as opioid users at all.
Fentanyl with xylazine is the one that has changed the clinical work most. Xylazine is a veterinary sedative and it is not an opioid, which means naloxone does not reverse it. Naloxone should still be given, because fentanyl is usually present too, but the sedation may not lift the way responders expect. Xylazine also causes severe skin wounds that can appear away from injection sites, and its withdrawal does not respond to opioid withdrawal medication.
Alcohol or benzodiazepines with opioids is the combination that makes withdrawal medically dangerous rather than merely difficult, for reasons covered below.
Very little of this is a person deciding to combine things. It is a supply in which what is sold and what is delivered have come apart.
Why Mixed Withdrawal Is a Harder Clinical Problem
Withdrawal is not additive. Different substances withdraw on different timelines, through different mechanisms, with different levels of risk, and they do not wait politely for each other.
Alcohol and benzodiazepines carry the mortality risk. Both suppress the central nervous system, and abrupt removal after sustained use can produce seizures and delirium tremens, a medical emergency involving the collapse of automatic regulation of heart rate, blood pressure, and temperature. This is the track that requires medical supervision regardless of what else is present.
Opioid withdrawal is rarely fatal directly but is severe enough that most people cannot complete it alone, and it is dangerous indirectly because tolerance falls fast. Returning to a previous dose after a few days without is where a large share of overdose deaths occur.
Put them together and the sequencing problem appears. Opioid withdrawal peaks while the alcohol or benzodiazepine risk window is still open. Managing one with medication can complicate the other. Xylazine adds a sedation and wound-care picture that neither protocol addresses. A person withdrawing from a mixed supply needs more than one protocol running at once, which is not something that can be improvised at home.
There is also a specific trap worth naming. Starting buprenorphine too early in someone with fentanyl in their system can trigger precipitated withdrawal, which is faster and more severe than the natural version. Fentanyl’s behavior in the body makes the timing harder to judge than it was with heroin, and it is a prescriber’s call rather than something to work out alone.
What This Changes About Overdose Response
Two findings from the state’s 2024 reporting are worth sitting with, because they point at something fixable.
A bystander was present at 54 percent of fatal overdoses. In 77 percent of those, nobody responded. Only 11 percent involved somebody witnessing the use itself, meaning most bystanders were nearby rather than watching. Naloxone was administered in 29 percent of cases, and in 78 percent of those it came only after a first responder arrived.
Massachusetts distributed 148,527 naloxone kits in 2024. The gap is not supply. It is that people were present and did not recognize what they were seeing, or did not have a kit within reach. Slow or stopped breathing, blue or gray lips and fingertips, and unresponsiveness to a hard sternal rub are the signs. Give naloxone, call 911, and give it even when you suspect a stimulant, because in this supply the distinction is unreliable.
What Complex Detox Looks Like in Practice
Serenity at Summit’s Haverhill campus provides medically monitored inpatient detox, which is ASAM Level 3.7, a designation that carries 24-hour nursing oversight on the unit as a structural feature of that level of care.
For a mixed presentation, that means assessment that assumes multiple substances rather than taking one at face value, because people underreport in good faith when they do not know what they were sold. Alcohol withdrawal severity is scored with CIWA-Ar, a standardized measure, and drives a symptom-triggered taper rather than a fixed schedule. Medication-assisted treatment with buprenorphine, methadone, or naltrexone is available for the opioid component with induction timed by a prescriber. More on the medications used in detox and on alcohol detox specifically.
Mental health care runs alongside rather than afterward, since co-occurring conditions are common in this population and treating the substances alone tends not to hold. Residential treatment is planned during the detox stay rather than left as an open question at discharge.
The Haverhill campus draws from across Essex County and the Merrimack Valley, including Lawrence, Andover, and Methuen, and reaches into southern New Hampshire along the 495 corridor.
Get an Assessment That Accounts for the Whole Picture
If you are not certain what you have been taking, that is now a normal answer rather than an embarrassing one, and it is information a clinical team can work with. An assessment establishes what is actually in play, whether withdrawal is medically dangerous in your case, and what level of care fits, and none of that requires having decided anything first. Families call to ask on someone else’s behalf regularly. Reach the Serenity at Summit admissions team, or check your benefits if cost is the thing in the way. If someone is unresponsive or their breathing has slowed or stopped, give naloxone and call 911 now.
Frequently Asked Questions About the Rise of Polysubstance Use in MA
It means more than one substance is present, and in Massachusetts it is now the default rather than the exception. State drug-checking analyzed in the 2024 opioid-involved overdose reporting found a median of four active substances plus two inactive ones per sample. Most of that is not people combining things deliberately. It is that what is sold and what is delivered have come apart, so somebody buying one drug frequently receives several without knowing it.
Naloxone reverses opioids, and xylazine, which now appears frequently alongside fentanyl, is a veterinary sedative rather than an opioid. Naloxone will not reverse its sedation, so someone may not wake up the way responders expect. Give naloxone anyway, because fentanyl is usually present too and reversing that part matters, then call 911 and stay with the person. The same logic applies with stimulants, since in this supply the distinction between what someone took and what they received is unreliable.
Generally yes, and the reason is that withdrawal is not additive. Alcohol and benzodiazepines carry genuine mortality risk through seizures and delirium tremens, while opioid withdrawal is rarely fatal directly but severe, and the timelines overlap rather than queue. Managing one with medication can complicate another, and xylazine adds a sedation and wound-care picture that neither standard protocol addresses. That combination is the clinical reason a mixed presentation needs medical supervision rather than a plan made at home.
That is now a common and entirely reasonable answer, and it is not something to be embarrassed about with a clinical team. Assessment for a mixed presentation assumes multiple substances rather than taking a single answer at face value, precisely because people underreport in good faith when they do not know what they were sold. Toxicology screening, withdrawal scoring, and medical history fill in what memory cannot, and the protocol is built from what is actually found.
